GlassScriptPhysician profile
Lawrence S Kim
NPI 1275647414
$4,420.03
in general payments reported to CMS, 2019-2025
33 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $80.19 · 2021: $290 · 2022: $927 · 2023: $1,251 · 2024: $701 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Education: $17.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.25 |
| Education | $17.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,497.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $609.46 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $350.98 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $342.59 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.80 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $235.19 | 2022-2025 | |
| Pfizer INC. | $216.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.89 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $112.54 | 2019-2024 | |
| Ardelyx, INC. | $109.10 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $78.04 | 2023-2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $40.01 | 2022 | |
| Shire North American Group INC | $39.68 | 2019 | |
| Qol Medical, LLC | $38.93 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $38.14 | 2025 | Iqirvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $37.98 | 2019 | |
| Phathom Pharmaceuticals, INC. | $30.48 | 2024 | Voquezna |
| Eli Lilly and Company | $29.56 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $28.83 | 2019-2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.06 | 2023 | Cyltezo |
| Celltrion USA INC. | $17.37 | 2023 | Yuflyma |
| Novo Nordisk INC | $16.76 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $16.64 | 2021 | |
| Shionogi INC | $15.83 | 2019 | |
| Gilead Sciences, INC. | $15.60 | 2019 | |
| Ethicon US, LLC | $15.08 | 2020 | |
| Ucb, INC. | $14.22 | 2019 | |
| Braintree Laboratories, INC. | $13.91 | 2022 | |
| Merck Sharp & Dohme LLC | $13.71 | 2019 | |
| Digestive Care, INC. | $13.32 | 2021 | |
| Organon LLC | $13.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.92 | 2022 | |
| Daiichi Sankyo INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.